Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
75.27
+0.51 (0.68%)
At close: May 1, 2026, 4:00 PM EDT
75.30
+0.03 (0.04%)
After-hours: May 1, 2026, 7:45 PM EDT
Ionis Pharmaceuticals Stock Forecast
Stock Price Forecast
The 22 analysts that cover Ionis Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $94, which forecasts a 24.88% increase in the stock price over the next year. The lowest target is $46 and the highest is $130.
Price Target: $94 (+24.88%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ionis Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 9 | 9 | 9 | 9 |
| Buy | 9 | 9 | 9 | 10 | 10 | 10 |
| Hold | 4 | 4 | 4 | 4 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 22 | 22 | 22 | 23 | 22 | 22 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $95 → $100 | Buy | Maintains | $95 → $100 | +32.86% | Apr 30, 2026 |
| Barclays | Barclays | Buy Maintains $106 → $115 | Buy | Maintains | $106 → $115 | +52.78% | Apr 30, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $120 → $125 | Strong Buy | Maintains | $120 → $125 | +66.07% | Apr 30, 2026 |
| TD Cowen | TD Cowen | Strong Buy Maintains $110 → $108 | Strong Buy | Maintains | $110 → $108 | +43.48% | Apr 23, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Initiates $110 | Strong Buy | Initiates | $110 | +46.14% | Apr 21, 2026 |
Financial Forecast
Revenue This Year
843.89M
from 943.71M
Decreased by -10.58%
Revenue Next Year
1.50B
from 843.89M
Increased by 77.99%
EPS This Year
-4.19
from -2.38
EPS Next Year
-1.36
from -4.19
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 955.6M | 2.2B | ||||||
| Avg | 843.9M | 1.5B | ||||||
| Low | 749.1M | 1.2B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1.3% | 155.8% | ||||||
| Avg | -10.6% | 78.0% | ||||||
| Low | -20.6% | 40.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -3.23 | 1.22 | ||||||
| Avg | -4.19 | -1.36 | ||||||
| Low | -4.60 | -3.88 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.